

Pediatric Supratherapeutic INR Guidelines

Bleeding Evaluation

- Inquire if any signs and symptoms of bleeding are present.
 - If symptoms of serious bleeding are present, hold warfarin and refer for immediate emergency evaluation.

Management in The Bleeding Patient ^{‡(1)}		
Any INR Serious or Life-Threatening Bleeding	Action	Comment
	<ul style="list-style-type: none">• Hold warfarin• Give vitamin K 5 mg IV by slow IV infusion<ul style="list-style-type: none">◦ May be repeated• Administer 3-factor prothrombin complex concentrate (PCC) 25-50 units/kg + Fresh Frozen Plasma (FFP) 10-15mL/kg.• Monitor INR every 12 hours.• PCC/FFP may be repeated after 6 hours for persistent INR elevation if necessary	<p>If PCC unavailable, FFP 10-15mL/kg is an alternative</p> <p>Recombinant Factor VIIa can be considered in highly urgent situations.</p>

- If no signs or symptoms of serious bleeding are present, the following guideline may be used:

INR Management in the non-bleeding patient ⁽²⁾		
INR	Action	Comment
Between 4.5 and 10	<ul style="list-style-type: none">• Omit one or two doses of warfarin• Monitor INR more frequently• Resume warfarin at adjusted dose when INR returns to therapeutic range	
Greater than 10	<ul style="list-style-type: none">• Hold warfarin• Give vitamin K 0.5-2 mg PO<ul style="list-style-type: none">◦ May be repeated• Monitor INR more frequently (e.g. 1-3 days) (give additional vitamin K if necessary)• Resume warfarin at an adjusted dose when INR returns to therapeutic range	Vitamin K decreases INR faster, but reduced bleeding remains unproven.

[‡]The decision regarding whether to resume anticoagulation (and if so the timing) must be individualized based upon the patient's clinical circumstances.

1. Streiff MB. The National Comprehensive Cancer Center Network (NCCN) guidelines on the management of venous thromboembolism in cancer patients. *Thromb Res* 2010 Apr;125 Suppl 2:S128-33.
2. Holbrook A, Schulman S, Witt DM, et al. Evidence-Based Management of Anticoagulant Therapy. *Chest* 2012 February 1, 2012;141(2 suppl):e152S-e84S.